Medicare Mailing Checks to Pay for Drugs

Medicare will begin mailing out tens of thousands of $250 checks today to senior citizens throughout the country as part of the Obama administration’s recently enacted health reform law.

Under the recently enacted law, seniors who fall within the ‘donut hole’ coverage gap in 2010 will receive a tax-free $250 rebate check from the government. The donut hole coverage gap is the period of the Medicare prescription drug benefit plan where the beneficiary pays 100 percent of the cost of drugs until they hit a threshold of $2,830. Medicare recipients will automatically receive the check for $250 once their drug costs hit the $2,830 mark.

“Prescription drugs cost many people thousands of dollars each year,” says U.S. Rep. Ciro D. Rodriguez, D-San Antonio. “These checks are the first step in reducing prescription drug costs for seniors and closing the donut hole entirely.”

By January 2011, seniors in the donut hole will receive a 50 percent discount on brand name drugs. By 2020, the donut hole should be completely closed, Rodriguez says.

Read more: Medicare to mail out $250 to seniors to help defray drug costs - San Antonio Business Journal

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap